{
    "nctId": "NCT00661531",
    "briefTitle": "Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy",
    "officialTitle": "A Single Arm Phase II Study of Pharmacologic Dose Estrogen in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapies",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Cancer of the Breast, Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 11,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed estrogen and/or progesterone receptor-positive breast cancer metastatic breast cancer\n* Clinically determined evaluable disease\n* Post-menopausal woman\n* Previous clinical benefit from prior anti-estrogen therapies and subsequent failure of at least 2 prior endocrine therapies.\n* May have had chemotherapy for adjuvant \\&/or metastatic disease.\n* May have had radiation therapy but not to the only site of disease.\n* Ecog performance status \\</= 2.\n* Life expectancy of \\> 6 months\n\nExclusion Criteria:\n\n* Chemotherapy or radiotherapy within 1 week of beginning treatment in the clinical trial\n* Brain metastasis\n* Prior history of or active thrombophlebitis, deep venous thrombosis or pulmonary embolus\n* Current vaginal bleeding\n* Hypercalcemia or hypocalcemia\n* History of or active hepatic adenoma\n* No other malignancies within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}